Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.38 |
| ▸ | JAK3 | P52333 | 12/20 | 0.38 |
| ▸ | JAK1 | P23458 | 8/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613101 | 0.94 | JAK2 (0.34) | JAK2JAK3JAK1CASP3BRD4 | |
| SCHEMBL25613114 | 0.85 | CHRNB4 (0.46) | — | |
| SCHEMBL25613112 | 0.83 | TDP1 (0.35) | — | |
| SCHEMBL25625028 | 0.80 | ALOX5AP (0.36) | JAK2JAK3CASP3ALOX5APCNR2 | |
| SCHEMBL25613103 | 0.80 | CHRNA3 (0.42) | — | |
| SCHEMBL25613102 | 0.79 | FEN1 (0.31) | JAK1 | |
| SCHEMBL25613092 | 0.78 | CDK2 (0.40) | — | |
| SCHEMBL25613094 | 0.78 | CDK2 (0.38) | ALOX5APCNR2 | |
| SCHEMBL25613097 | 0.74 | CHRNB4 (0.39) | — | |
| SCHEMBL25613093 | 0.74 | CHRNA3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | JAK2 431/4885JAK3 3456/4885JAK1 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.